News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug
View HTML
Toggle Summary Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
-- Relying upon Scientific Advisory Group input, Sarepta will seek further scientific advice from European Medicines Agency on a possible path to bring eteplirsen to patients in Europe -- CAMBRIDGE, Mass. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
CAMBRIDGE, Mass. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic medicines for the treatment of rare neuromuscular and other rare diseases, will ring Nasdaq’s Opening
View HTML
Toggle Summary Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases and other rare diseases, today announced that
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on August 31, 2018 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
-- 10 academic scholarships awarded to students diagnosed with Duchenne muscular dystrophy as they pursue their post-secondary education this fall -- CAMBRIDGE, Mass. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused
View HTML
Toggle Summary Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
Second quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $73.5 million CAMBRIDGE, Mass. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to
View HTML
Toggle Summary Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools
-- Sarepta expands its presence in gene therapy and broadens its reach with license to up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s  gene therapy candidate for Pompe Disease and options to two additional candidates -- -- Sarepta will make an equity
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , July 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on July 31, 2018 , that were
View HTML
Toggle Summary Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events
-- Out-of-specification lot resulted from the presence of trace levels of DNA fragment in research-grade raw material plasmid sourced from third-party manufacturer -- -- Fragment fully characterized; preliminary testing and analysis indicates no safety signals -- -- Subject to FDA review of a
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.